证券代码：301509 证券简称：金凯生科 公告编号：2024-017 金凯（辽宁）生命科技股份有限公司 2023 年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形； 2、召开地点：金凯（辽宁）生命科技股份有限公司会议室。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召开时间： （1）现场会议时间：2024 年 4 月 23 日（星期二）下午 14：00。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2024 年 4 月 23 日的交易时间，即 9:15-9:25、9:30—11:30 和 13:00— 15:00；通过深圳证券交易所互联网系统投票的具体时间为 2024 年 4 月 23 日 9:15—15:00。 3、召开方式：本次股东大会采用现场表决与网络投票相结合的方式召开。 4、召集人：公司董事会。 5、主持人：董事长 FUMIN WANG（王富民）先生。 6、本次会议的召集、召开符合《中华人民共和国公司法》《上市公 ...

北京市中伦（青岛）律师事务所 关于金凯（辽宁）生命科技股份有限公司 2023 年度股东大会的 法律意见书 二〇二四年四月 北京市中伦（青岛）律师事务所 关于金凯（辽宁）生命科技股份有限公司 2023 年度股东大会的 法律意见书 致：金凯（辽宁）生命科技股份有限公司 北京市中伦（青岛）律师事务所（以下简称"本所"）接受金凯（辽宁）生 命科技股份有限公司（以下简称"公司"）的委托，根据本法律意见书出具日前 已经发生或存在的事实和《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 《律师事务所从事证券法律业务管理办法》《律师事务所证券法律业务执业规则 （试行）》等中华人民共和国（以下简称"中国"，为本法律意见书之目的，不 包括香港特别行政区、澳门特别行政区和台湾地区）现行有效的法律、法规和 规范性文件以及《金凯（辽宁）生命科技股份有限公司章程》（以下简称"《公 司章程》"）、《金凯（辽宁）生命科技股份有限公司股东大会议事规则》（以下简 称"《股东大会议事规则》"）等有关规定，指派律师出席公司于 2024 年 4 月 23 日召开的 2023 ...

Financial Performance - The company's revenue for Q1 2024 was ¥124,332,621.75, a decrease of 41.87% compared to ¥213,889,447.06 in the same period last year[4] - Net profit attributable to shareholders was ¥16,741,205.71, down 58.83% from ¥40,666,713.67 year-on-year[4] - Basic and diluted earnings per share decreased by 69.84% to ¥0.19 from ¥0.63 in the same period last year[4] - Total operating revenue for Q1 2024 was CNY 124,332,621.75, a decrease of 41.8% compared to CNY 213,889,447.06 in the same period last year[20] - The net profit for Q1 2024 was CNY 16,741,205.71, a decrease of 58.8% compared to CNY 40,666,713.67 in Q1 2023[21] - Total operating income for Q1 2024 was CNY 20,066,982.38, down from CNY 49,009,645.28 in the same period last year[21] - The company reported a total comprehensive income of CNY 17,005,810.60 for Q1 2024, down from CNY 38,703,148.36 in Q1 2023[21] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly to ¥74,538,568.94, compared to a negative cash flow of ¥24,462,228.52 in the previous year, representing a 404.71% improvement[4] - Cash flow from operating activities generated a net amount of CNY 74,538,568.94, a significant improvement from a net outflow of CNY 24,462,228.52 in Q1 2023[23] - Cash and cash equivalents increased to CNY 536,014,618.49 from CNY 486,901,359.23, reflecting a growth of 10.4%[18] - Cash and cash equivalents at the end of Q1 2024 totaled CNY 536,014,618.49, compared to CNY 223,449,259.92 at the end of Q1 2023[24] - Operating cash inflows totaled CNY 181,469,978.88, an increase from CNY 141,122,526.44 in the previous year[23] - The company incurred total operating cash outflows of CNY 106,931,409.94, down from CNY 165,584,754.96 in Q1 2023[23] - The net cash flow from investing activities was negative CNY 21,447,108.10, compared to a positive CNY 38,011,094.89 in Q1 2023[23] - The company experienced a foreign exchange impact of CNY 1,074,957.31 on cash and cash equivalents during the quarter[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,295,075,903.84, a slight decrease of 0.67% from ¥2,310,635,609.21 at the end of the previous year[4] - Total assets decreased to CNY 2,295,075,903.84 from CNY 2,310,635,609.21, a decline of 0.7%[19] - Total liabilities decreased to CNY 105,693,583.02 from CNY 139,630,803.20, a reduction of 24.3%[19] - The company's total equity increased to CNY 2,189,382,320.82 from CNY 2,171,004,806.01, reflecting a growth of 0.8%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,569, with the largest shareholder holding 48.66% of the shares[10] - The company reported a total of 65,634,680 shares with 1,109,680 shares released from restrictions during the period, leaving 64,525,000 shares under restriction[13] - Kingchem (China) Holding LLC holds 41,863,773 shares, which are subject to a lock-up until February 3, 2027[13] - The top ten unrestricted shareholders include Bai Qingliang with 341,400 shares and Xingye Bank with 215,000 shares[11] - The company has a total of 7,500,000 shares held by Qilu (Xiamen) Equity Investment Partnership, which are also subject to a lock-up until August 3, 2024[13] - The company has no changes in the top ten shareholders due to securities lending or borrowing activities[11] - The total number of shares held by the top ten unrestricted shareholders is 1,109,680 shares, which were released from restrictions on February 5, 2024[13] - The company has a total of 3,933,911 shares held by Blue Economy Zone Industrial Investment Fund, which are subject to a lock-up until August 3, 2024[13] Operational Efficiency - The company experienced a 39.37% reduction in operating costs, which amounted to ¥75,352,404.76 compared to ¥124,289,242.50 in the previous year[8] - Total operating costs for Q1 2024 were CNY 110,839,890.09, down 32.3% from CNY 164,128,214.79 in the previous year[20] - Research and development expenses for Q1 2024 were CNY 6,964,404.48, down from CNY 8,197,380.38 in the previous year, indicating a decrease of 15.0%[20] - Accounts receivable decreased by 46.04% to ¥55,911,064.26, primarily due to the collection of large receivables from the beginning of the year[7] - Accounts receivable decreased significantly to CNY 55,911,064.26 from CNY 103,618,656.11, a reduction of 46.0%[18] Governance - The company held its first temporary shareholders' meeting on January 9, 2024, to elect the second board of directors and supervisory board[15] - The company has completed the election of its second board of directors and supervisory board, ensuring continuity in governance[15] - The company has no preferred shareholders or changes in restricted shares during the reporting period[12] Government Support and Investment - The company reported a significant increase in government subsidies, totaling ¥1,236,991.05, which is a 165.28% increase compared to ¥466,304.69 in the previous year[8] - Investment income rose to ¥1,596,683.03, marking an increase of 185.93% from ¥558,421.85 year-on-year[8] - The company reported a net profit of CNY 1,596,683.03 from investments, an increase compared to CNY 558,421.85 in the previous year[20]

中信建投证券股份有限公司 关于金凯（辽宁）生命科技股份有限公司 2023 年度持续督导定期现场检查报告 | 保荐机构名称：中信建投证券股份有限公司 | 被保荐公司简称：金凯生科 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 保荐代表人姓名：逯金才 | | | | | 联系电话：010-5605 2488 | | | 保荐代表人姓名：张林 | | | | | 联系电话：010-5605 1430 | | | 现场检查人员姓名：逯金才 | | | | | | | | 现场检查对应期间：2023 年度（金凯生科于 2023 年 8 月 | 日上市） | | | | 3 | | | 年 月 月 日 现场检查时间：2024 3 29 日-3 30 | | | | | | | | 一、现场检查事项 | | 现场检查意见 | | | | | | （一）公司治理 | 是 | | 不适用 | 否 | | | | 现场检查手段（包括但不限于本指引第 33 | | | | 条所列）：查阅公司章程、公司治理制度以及三会会 | | | | 议资料、信息披露文件等 | ...

Financial Performance - The company reported a revenue of RMB 500 million for the fiscal year 2023, representing a 20% increase compared to the previous year [24]. - The company's operating revenue for 2023 was ¥766,824,305.02, representing a 7.00% increase from ¥716,670,015.13 in 2022 [29]. - Net profit attributable to shareholders for 2023 was ¥173,574,166.37, up 7.51% from ¥161,450,526.85 in 2022 [29]. - The net profit after deducting non-recurring gains and losses was ¥167,843,305.36, a 9.45% increase from ¥153,346,604.86 in 2022 [29]. - The gross margin for the CDMO sector improved to 47.43%, an increase of 3.48% compared to the previous year [54]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 15% year-over-year growth [105]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a year-over-year growth of 25% [185]. Market Expansion and Growth Strategies - The company is focused on expanding its market presence and enhancing its service offerings in the life sciences sector [5]. - The company is expanding its market presence in Europe, targeting a 10% market share within the next two years [24]. - The company plans to enter two new international markets by the end of the next fiscal year [163]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years [185]. - The company is exploring partnerships with international pharmaceutical firms to enhance distribution channels [24]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for potential deals [163]. Research and Development - The company plans to increase its R&D budget by 15% in the upcoming year to support ongoing clinical trials [24]. - The company has invested RMB 50 million in new technology for drug formulation processes, improving efficiency by 30% [24]. - The company is investing in R&D, allocating 10% of its revenue, approximately 120 million RMB, to develop new technologies [105]. - The company is investing 200 million yuan in R&D for new technologies aimed at enhancing product efficacy and user experience [180]. - The company has a number of clinical-stage projects in its pipeline, which could lead to explosive growth if any of these products are approved for market [48]. Corporate Governance and Compliance - The company is committed to maintaining high standards of corporate governance and transparency in its operations [5]. - The company has established a comprehensive governance structure that complies with relevant laws and regulations, ensuring effective decision-making and oversight [94]. - The company has established independent decision-making and supervisory bodies, ensuring no interference from controlling shareholders [99]. - The company has a robust investor relations management system, ensuring timely and accurate information disclosure [96]. - The company has established a shareholder return plan for the next three years, emphasizing the importance of cash dividends [134]. Risks and Challenges - The company faces risks including service disconnection, demand fluctuations, intensified competition, and production safety issues [5]. - The company is exposed to foreign exchange risks, particularly fluctuations in the RMB/USD exchange rate, which can impact its sales revenue and foreign exchange gains or losses [88]. - Environmental and safety production pressures are increasing as the company expands its operations, posing risks related to equipment failures and compliance with safety measures [88]. - The company faces risks from intensified industry competition due to significant investments in the domestic CDMO sector and potential unfair advantages held by overseas competitors [88]. Sustainability and Environmental Initiatives - The company emphasizes its commitment to sustainability, aiming to reduce operational carbon emissions by 15% over the next three years [105]. - The company has implemented a green manufacturing strategy, significantly reducing waste emissions and energy consumption, and was awarded the title of "Green Factory" in 2023 [149]. - The company has established effective waste gas treatment processes, including high-temperature incineration and advanced filtration systems, to meet emission standards [150]. - The company has committed to sustainability initiatives, with plans to reduce carbon emissions by 30% over the next five years [185]. Shareholder Returns and Dividends - The company reported a cash dividend of 8.00 CNY per 10 shares, totaling approximately 68.83 million CNY for all shareholders [6]. - The cash dividend represents 100% of the total profit distribution amount, with no shares being distributed as redemptions [134]. - The company plans to distribute a cash dividend amounting to 15%, not exceeding 50% of the total cash dividends received since its listing [177]. Internal Controls and Audit - The internal control system is compliant with legal requirements and effectively supports the company's strategic implementation [138]. - The internal control audit report indicates that as of December 31, 2023, the internal controls related to financial statements were effectively maintained in all material aspects according to the Basic Norms for Enterprise Internal Control [142]. - The company has established a dedicated department for safety production and environmental protection, continuously investing in safety and environmental facilities and capabilities [159]. Employee Management and Structure - The total number of employees at the end of the reporting period is 808, including 758 at the parent company and 50 at major subsidiaries [129]. - The company has established a competitive salary system based on job value, individual capability, and performance, ensuring fairness internally and competitiveness externally [131]. - The company emphasizes employee rights protection, providing timely salary payments and various welfare benefits, including housing subsidies for college graduates [158].

中信建投证券股份有限公司 关于金凯（辽宁）生命科技股份有限公司 2023 年度内部控制评价报告的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"、"保荐机构"）作为金凯 （辽宁）生命科技股份有限公司（以下简称"金凯生科"、"公司"）首次公开发行股票 并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》及《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》 等有关规定，对金凯生科 2023 年度内部控制评价报告进行了核查，具体情况如下： 一、公司内部控制的基本情况 （一）公司建立内部控制制度的目标 公司内部控制的目标是合理保证公司经营管理合法合规、资产安全、财务报告及相 关信息真实完整，提高经营效率和效果，促进公司实现发展战略。 （二）建立内部控制制度遵循的基本原则 1、合法性原则。内部控制应当符合法律、行政法规的规定和有关政府监管部门的 监管要求。 2、全面性原则。内部控制应当贯穿决策、执行和监督全过程，覆盖公司及其分公 司、子公司的各种业务和事项。 3、重要性原则 ...

证券代码：301509 证券简称：金凯生科 公告编号：2024-016 金凯（辽宁）生命科技股份有限公司 关于举行2023年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）已于2024年4月2 日在巨潮资讯网（www.cninfo.com.cn）披露了公司《2023年年度报告》及 《2023年年度报告摘要》。为便于广大投资者更全面深入了解公司经营业绩、 发展战略等情况，公司将举行2023年度网上业绩说明会，现将相关事项公告如下： 1.召开时间：2024年4月8日（星期一）15:00-16:30。 2.出席人员：公司董事长兼总裁FUMIN WANG(王富民）先生、财务总监兼董 事会秘书王琦先生、独立董事郭玉坤先生、中信建投证券股份有限公司保荐代 表人逯金才先生（如有特殊情况，参加人员将或有调整）。 4.问题征集：为充分尊重投资者，提升公司与投资者之间的交流效率和针对性， 公司就2023年度业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和 建议，投资者可于2024年4月7日上午9 ...

一、监事会会议召开情况 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）第二届监事会第 二次会议于2024年3月30日上午10时在公司会议室以现场会议结合通讯方式召开。 本次会议通知于2024年3月19日以当面送达或邮件方式发出。在保障所有监事充分 表达意见的情况下，本次会议采用现场结合通讯方式进行表决，会议应到监事3名， 实到监事3名，其中监事李昌浩、监事王乃伟以通讯方式出席，保荐代表人逯金才、 张林通讯列席。会议由监事会主席刘焕明先生主持，符合《中华人民共和国公司 法》等法律、法规和《金凯（辽宁）生命科技股份有限公司章程》的有关规定。 本次会议合法、有效。 二、监事会会议审议情况 1、审议通过《关于<2023 年年度报告>及其摘要的议案》 证券代码：301509 证券简称：金凯生科 公告编号：2024-011 金凯（辽宁）生命科技股份有限公司 第二届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 经审议，监事会认为公司董事会编制和审核的《2023年年度报告》《2023年 年度报告摘要》的程序符合相关法律、法规和中国证监会的规定 ...

金凯（辽宁）生命科技股份有限公司 2023 年度内部控制评价报告 金凯（辽宁）生命科技股份有限公司全体股东： 根据《企业内部控制基本规范》《企业内部控制应用指引》《企业内部控制评 价指引》以及《企业内部控制审计指引》的要求，公司结合自身的经营特点与所处 环境，不断完善集团治理，规范集团运作。在内部控制日常监督和专项监督的基础 上，我们对 2023 年度公司内部控制体系的建立、实施和内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有 效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和 实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公司董事 会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假记载、误 导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相 关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的 固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化可能导 致内 ...

金凯（辽宁）生命科技股份有限公司董事会 关于 2023 年度独立董事独立性自查情况的专项意见 董事会 根据《 中华人民共和国公司法》 上市公司独立董事管理办法》 深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规和规范性 文件及《 金凯《（辽宁）生命科技股份有限公司章程》《 金凯《（辽宁）生命科技股份有 限公司独立董事工作规则》的相关规定，金凯《（辽宁）生命科技股份有限公司《（以下 简称《 公司"）就 2023 年度在任独立董事刘媛媛女士、游松先生、郭玉坤先生提交的 2023 年度独立董事独立性自查情况报告》进行评估并出具如下专项意见： 经核查独立董事刘媛媛女士、游松先生、郭玉坤先生的任职经历以及签署的相关 自查文件，上述人员未在公司担任除独立董事以外的任何职务，其配偶、父母、子女、 主要社会关系也未在公司任职，也未在公司主要股东公司担任任何职务，与公司以及 主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系。因此，公 司独立董事符合《 上市公司独立董事管理办法》 深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》中对独立董事独立性的相关 ...